VolitionRX Ltd Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)1.10 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $0.26Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $7.8M Enterprise Value $12M Shares Outstanding 27.9M diluted Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary VolitionRx is a clinical-stage epigenetics company making significant scientific and commercial strides with its Nu.Q and Capture-Seq platforms. The company recently reported a 300% year-over-year revenue increase in Q1 2026 to $1 million and announced a high-profile collaboration with Sysmex Corporation to optimize its Nu.Q NETs assay. However, VolitionRx faces severe financial headwinds, including a going concern warning, a weak cash position of $3.1 million at Q1-end, and ongoing operating losses. While the long-term upside is substantial given its multi-billion-dollar addressable markets, the immediate liquidity risks and dilutive capital raises warrant a cautious Hold rating until non-dilutive milestone payments are secured. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$16.83 Mean target$20.21 High · most bullish analyst$24.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The feline milestone payment is delayed, and the company is forced to execute highly dilutive equity offerings or debt conversions to fund operations. Optimization with Sysmex encounters technical hurdles, slowing commercial progress. The company fails to meet its NYSE American compliance milestones, leading to delisting to the OTC market. Base CaseCentral scenario The company successfully optimizes its Nu.Q NETs assay on Sysmex's platform, paving the way for global commercialization. The feline lymphoma manuscript is published, unlocking a critical $5 million milestone payment that temporarily stabilizes the cash runway. Operating expenses continue to decline, and the company executes its NYSE American compliance plan, avoiding delisting. Bull CaseUpside scenario VolitionRx's bull case is driven by its proprietary Nucleosomics platform (Nu.Q), which targets a massive $27.8 billion total addressable market across human cancer detection ($23B), sepsis/NETosis ($3.8B), and veterinary diagnostics ($1B+). Key growth drivers include: (1) Commercial momentum with 300% YoY revenue growth in Q1 2026 ($1.0 million); (2) Near-term veterinary milestones, including an expected $5 million contractual payment upon peer-reviewed publication of its Nu.Q Vet feline lymphoma study; (3) Active licensing discussions with over a dozen global diagnostic leaders; (4) Breakthrough clinical validation of its Capture-Seq platform, which demonstrated >95% sensitivity for Stage I and II cancers; and (5) Progress toward European reimbursement for Nu.Q Lung Cancer in France by the end of 2026. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |